Condition
Malignant Pleural Mesothelioma (MPM)
Estimated Enrollment: 16
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: IRB14-1519
Study First Received: January 20, 2016
Last Updated: October 13, 2016
Estimated Primary Completion Date: February 2018
Primary Outcome Measures:
Proportion of patients who show in vitro cytotoxic T lymphocyte induction to at least 2 of the 5 antigens determined by Enzyme-Linked ImmunoSpot (ELISPOT) assay|Toxicity per Common Terminology Criteria for Adverse Events (CTCAE) v4.03|Disease control rate defined as the proportion of patients who are assessed as having complete response (CR), partial response (PR), or stable disease (SD) (>3 months)|6-month progression-free survival (PFS) rate|Peptide-specific cytotoxic T lymphocyte response determined by Enzyme-Linked ImmunoSpot (ELISPOT) assay
Sponsors and Collaborators:
University of Chicago
Website Link: https://ClinicalTrials.gov/show/NCT02661659
